ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study.
Article in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite recent improvements in treatment, outcomes for patients with pretreated, advanced triple-negative breast cancer (TNBC) remain poor. We present results from the phase I/II TROPION-PanTumor02 study of datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate (ADC) comprised of a humanised anti-trophoblast cell surface antigen 2 (TROP2) monoclonal antibody conjugated to a potent topoisomerase I (Topo-I) inhibitor, in Chinese patients with pretreated, advanced TNBC. Methods: Patients received Dato-DXd 6 mg/kg intravenously every 3 weeks until radiological progression or another discontinuation criterion was met. The primary endpoint was objective response rate (ORR) per independent central review (ICR); secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: At data cutoff (6 May 2024), 79 patients had received treatment. Median age was 50.0 years (range, 33-73 years) and 74 (93.7%) patients had metastatic disease; 33 (41.8%) had liver metastases. Patients had received a median of 3 (range, 2‒8) prior lines of chemotherapy for advanced disease [≥5 lines, n=21 (26.6%)]. ORR by ICR was 33.8% [95% confidence interval (CI): 23.4-45.4%]. Median PFS and OS were 5.3 months (95% CI: 4.2-6.9) and 13.5 months [95% CI: 10.7-not calculable (NC)], respectively. The most common treatment-related adverse events (TRAEs) were stomatitis (49.4%) and nausea (43.0%). Twenty-five patients (31.6%) experienced grade ≥ III TRAEs. Adjudicated drug-related interstitial lung disease (ILD) was reported in 1 patient (grade II). Conclusions: Dato-DXd monotherapy demonstrated clinical activity and manageable safety in Chinese patients with heavily pretreated, advanced TNBC. Phase III studies of Dato-DXd alone or in combination in early-stage and advanced TNBC are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.